Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia

    Research output: Contribution to journalArticle

    20 Citations (Scopus)

    Abstract

    ISIS-301012 is an antisense oligonucleotide inhibitor of apolipoprotein B-100, which is being developed by Isis Pharmaceuticals Inc for the potential treatment of hypercholesterolemia. A subcutaneous injectable formulation is currently undergoing phase II clinical trials, while phase I trials are underway with an oral formulation of the drug.
    Original languageEnglish
    Pages (from-to)461-467
    JournalCurrent Opinion in Molecular Therapeutics
    Volume8
    Issue number5
    Publication statusPublished - 2006

    Fingerprint Dive into the research topics of 'Drug evaluation: ISIS-301012, an antisense oligonucleotide for the treatment of hypercholesterolemia'. Together they form a unique fingerprint.

    Cite this